Study of senl103 for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called SENL103 for people with multiple myeloma that has come back or not responded to several prior treatments. The drug aims to target and kill myeloma cells, potentially helping those who have few other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have multiple myeloma that has returned or not responded to at least 3 prior treatments, including certain standard therapies.
- You have measurable signs of the disease (e.g., specific protein levels in blood or urine, or a certain percentage of clonal cells in bone marrow).
- You have not had prior BCMA-targeted therapy or CAR-T cells.
- You do not have serious heart problems, active autoimmune disease, or lung disease (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.